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TITLE: PREVALENCE OF HYPOTHYROIDISM & 
HYPERPROLACTINEMIA IN BENIGN BREAST DISEASE  
• AIM & OBJECTIVE :A. TO EVALUATE THE PREVALENCE OF 
HYPOTHYROIDISM IN BENIGN BREAST DISEASE    
                                 B.PREVALENCE OF HYPERPOLACTINEMIA IN 
BENIGN BREAST DISEASE  
• DESIGN OF STUDY : PROSPECTIVE STUDY  
• PERIOD OF STUDY : 1 YEAR 
• COLLABERATING DEPARTMENT : MEDICAL ENDOCRINOLOGY 
& BIOCHEMISTRY  
• CRITERIA FOR SELECTION : ALL PATIENTS SATISFYING 
INCLUSION CRITERIA EITHER ADMITTED IN GOVT RAJAJI 
HOSPITAL OR TREATED ON OPD BASIS FOR A PERIOD OF 1 YEAR 
• ELIGIBILITY CRITERIA :  
• INCLUSION CRITERA : PATIENTS OF REPRODUCTIVE AGE 
GROUP DIAGNOSED AS  
(A) FIBROADENOMA  (B) FIBROADENOSIS  
(C) FIBROCYSTIC BREAST DISEASE  
               PATIENTS CONENTED FOR INCLUSION IN THE STUDY 
ACCORDING TO THE DESIGNATED PROFORMA  
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• EXCLUSION CRITERIA : ALL THE PATIENTS PRESENTING 
WITH LUMP SUGGESTIVE OF MALIGNANCY,ULCERATIVE 
BREAST LESION, PREGNANCY & LACTATION  
PATIENTS NOT CONENTED FOR INCLUSION IN THE STUDY  
• SELECTION OF STUDY SUBJECTS : ALL PATIENTS DIAGNOSED 
AS HAVING BENIGN BREAST DISEASE COMING UNDER THE 
INCLUSION CRITERIA FOR THE ABOVE MENTIONED TIME 
PERIOD AND THEIR SERUM PROLACTIN LEVELS AND TSH 
LEVELS  
• METHOD OF STUDY : PROSPECTIVE STUDY  
• CONENT : INDIVIDUAL WRITTEN & INFORMED CONENT  
• ANALYSIS : STATISTICAL ANALYSIS  
• CONFLICT OF INTEREST : NONE  
• FINANCIAL SUPPORT : NIL FROM THE INSTITUTION  
12. PARTICIPANTS: ALL PATIENTS FROM CASUALITY ,SURGERY 
OPD DIAGNOSED TO HAVE BENIGN BREAST DISEASE COMING 
UNDER THE INCLUSION CRITERIA FOR THE ABOVE MENTIONED 
TIME PERIOD 
LIST OF ABBREVATIONS : 
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Fdn- Fibroaenoma 
Fds- Fibroadenosis 
b/l Fds- Bilateral fibroadenosis  
Fcs- Fibrocystic breast disease  
b/l  Fcs- Bilateral fibrocystic breast disease  
BBD – Benign Breast Diseases  
LUQ- Left upper quadrant of breast  
RUQ- Right upper quadrant of breast  
LLQ- Left lower quadrant of breast  
RLQ- Right lower quadrant of breast  
NIS- Sodium iodide symporter  
TSH- Thryroid stimutaling hormone 
T4- Thyroxine  
TDLU- Terminal duct lobular unit 
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INTRODUCTION  
∗ Mammary glands have physical as well as psychological importance in 
human females. Benign breast disease constitute the major workload in 
breast clinics. A comprehensive classification which puts all of these process 
of physiological changes,growth,development & involution is 
ANDI(Abberation of normal development and involution) classification. 
This includes six conditions, two are developmental (adolescent hypertrophy 
and fibroadenoma) , two are cyclical (mastalgia and cyclical nodularity) and 
two are involutionary (cyst formation and sclerosing adenosis).  
∗ “Prolactin plays an important role in the proliferation and differentiation of 
normal breast epithelium”.  It is suggested that patients with benign lumps 
and pain should be screened for clinical or laboratory evidence of 
hyperprolactinemia. Prolactin is responsible for structural growth & 
secretory differentiation of breast .It could be end organ hypersensitivity to 
high circulating levels of prolactin or few dietary influences that is 
responsible for benign breast disease. Pharmacological treatment of 
hyperprolactinemia in patients having raised serum levels can provide relief 
from symptoms of benign breast disease. 
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∗ NIS (Sodium Iodide symporter) expression was observed to be significantly 
higher in malignant compared to normal breast tissue with highest levels in 
fibroadenoma. Both normal & pathological breast tissue exhibit high 
concentration of NIS, peroxidase & deiodinase indicating active 
involvement of breast tissue in iodine metabolism. Due to the activity of 
sodium iodide symporter activity in breast tissue at certain stages of life 
breast tissue is actively involved in iodine uptake. Outcome of Benign breast 
disease patients with hypothyroidism can be improved by thyroid 
replacement therapy. We performed a prospective study to look into thyroid 
dysfunction in patients with benign breast disease.  
∗ The aim of this study was to investigate the prevalence of 
Hyperprolactinemia and Hypothyroidism in patients diagnosed as 
having Benign Breast disease. 
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REVIEW OF LITERATURE: 
EMBRYOLOGY OF BREAST  
The mammary glands are modified sweat glands and are ectodermal in origin. The 
epithelial lining of the ducts and the alveoli are derived from ectoderm and 
supporting fatty tissue and blood vessels by mesenchyma during 6th week of 
embryonic life. An ectodermal thickening extends on either side of the midline 
from axilla to groin. This thickening is called “mammary ridge” or milk line, 
accessory mammary glands (polymastia) or accessory nipples(ploythelia) may 
occur along the milk line.  
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FIG 1: The extent of foetal mammary ridge. Accessory nipples or breasts are 
usually found along this line. 
In humans, these ridges normally disappear except at the site of the breast. The 
remnant of the milk line produces a “primary bud of the mammary gland at 5th 
week. This bud grows down into the underlying dermis. In the 10th week the 
primary bud begins to branch and by 12th week several secondary buds have 
formed”. These buds lengthen and branch through the remainder of gestation and 
resulting ducts canalize. 
“At birth, the mammary gland consists of 15-25 lactiferous ducts, which opens into 
a small superficial depression called “mammary pit”. Proliferation of the 
underlying mesoderm converts the pit into inverted nipple within few weeks after 
birth. These structures under influence of hormones during puberty, pregnancy and 
lactation increase in size in female breast. 
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FIG-2: Development of mammary glands 
A: 28 days embryo showing mammary crests. B: 6 weeks, showing remains of the 
crests. 
C, D, E, F : successive stages in the development between 12th week and birth. 
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FIG-3: Phases of Human Breast Development: 
Sketches showing progressive stages in the postnatal development of the breasts. 
A-Newborn. B-Child. C-Early puberty. D-Late puberty. E- Young adult. F-
Pregnant female. 
Female Breast Development & its Endocrine Control 
Breast development commences with secretion of cyclical estrogen and the 
progesterone secretion at puberty. Estrogen is responsible for the differentiation of 
peri-ductal stroma and growth of the ducts that elongate and acquire a thickened 
epithelium. Growth hormone and gluco-corticoids also contribute to ductal growth. 
Lobules are derived from solid masses of cells that form at the end of terminal 
ducts. Lobulo-alveolar differentiation and the growth during this puberty time are 
stimulated and increased primarily by insulin, progesterone and growth hormone . 
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Though the greatest amount of breast glandular differentiation occurs at puberty, 
the differentiation process continues into the second decade and is further 
enhanced by pregnancy. The evolution of breast from childhood to maturity has 
been divided into 
FIVE PHASES OF TANNER: 
Phase I (age: puberty): there will be Pre adolescent elevation of the nipple. There 
will be no palpable glandular tissue or areolar pigmentation. 
Phase II (age: 11.1 ± 1.1 yr) : Presence of glandular tissue in the sub areolar 
Region of breast. The nipple and breast project as a single mound from the chest 
wall. 
Phase III (age: 12.2 ± 1.09 yr) : Increase in the amount of readily palpable 
Glandular tissue and enlargement of the breast with increased diameter and 
pigmentation of the areola. The contour of the breast and nipple remains in a single 
plane. 
Phase IV (age: 13.1 ± 1.15 yr) : Enlargement of the size of areola and 
increased areolar pigmentation. The nipple and areola form a secondary mound 
above the level of the breast. 
 
Phase V (age: 15.3 ± 1.7 yr) : There will be final adolescent development of a 
smooth contour with no projection of the areola and nipple 
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ANATOMY OF BREAST  
The breast is “located within the superficial fascia of the anterior thorasic wall. It 
consists of 15-20 lobes of glandular tissue of  tuboalveolar type. Fibrous 
connective tissue forms a framework that supports the lobes, and adipose tissue 
fills the space between the lobes”. 
“Subcutaneous connective tissue surrounds the gland and extends as septa between 
the lobes and lobules, providing support for the glandular elements, but it doesnot 
form a distinctive capsule around the components of the breast”. 
The deep layer of superficial fascia, which lies on the posterior (deep) surface of 
the breast, rests on the pectoral(deep) fascia of the thorasic wall. A distinct space, 
the retromammary bursa, can be identified surgically on the posterior aspect of the 
breast between the between the deep layer of superficial fascia and the deep 
investing fascia of the pectoralis major and contiguous muscles of the thorasic 
wall. Fibrous thickening of connective tissue extends from the deep layer of 
superficial fascia and attaches to the dermis of the skin. These are called cooper’s 
ligaments, insert perpendicular to the delicate superficial facial layers of the dermis 
or cornium, permitting mobility to the breast while providing support.  
At maturity, the glandular portion of the breast has a unique and distinctive conical 
form.  Commonly breast tissue extends into axilla as the axillary tail   (of spense).  
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“The breast of the nulliparous female has a typical hemispheric configuration with 
distinct flattening above the nipple. The multiparous breast, which has experienced 
the hormonal stimulation associated with pregnancy and lactation, the breast 
increases dramatically in size and becomes pendulous.” 
The greater part of the breast, about 2/3rds rests on pectoralis major muscle and 
1/3rd on serratus anterior muscle. At its lower medial quadrant, the gland rests on 
the aponeurosis of the external oblique which separates it from rectus abdominis.  
 
 
FIG-4: ANATOMY OF BREAST  
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EXTENT AND LOACATION: 
 “The mature female breast extends inferiorly from the level of the second or 
third rib to the inframammary fold which is about the level of sixth or seventh rib, 
and laterally from the lateral border of the anterior or midaxillary line. The deep or 
posterior surface of the breast rests on portions of the deep investing fascia of the 
pectoralis major, serratus anterior, external oblique and upper extent of the rectus 
sheath” 
AXILLARY TAIL OF SPENCE:  
“The upper outer quadrant of the breast tissue projects and passes through an 
opening in the axillary fascia called “foramina of langer” at the level of 3rd rib in 
axilla”. This is called axillary tail of Spence. This is in direct contact with the main 
glands of the breast and hence may be mistaken for axillary lymphadenopathy. The 
axillary tail is deep to deep fascia although the breast proper is superficial to the 
axillary fascia.  
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FIG-5: AXILLARY TAIL OF SPENCE  
 
NIPPLE (MAMMARY PAPILLA) : 
The skin over the centre of breast is modified to form areola and nipple. Nipple 
projects centrally. Its shape is conical and its level is at 4th intercostals space in 
most of young women. Its color varies from pink to light or dark brown depending 
upon parity, race and general melanization of body.  
The bulk of the nipple is made up of smooth muscle fibers which are arranged 
circularly and longitudinally. Contraction of these fibers tends to make the nipple 
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erect. The lacticiferous ducts traverse the nipple through 15-20 minute orifices and 
opens at its tip.  
The areola in young females is convex and lens shaped. Its color varies from pink 
to dark brown. The nipple and areola contain many sebaceous glands which 
enlarge during pregnancy and lactation as “Montogmery tubercles” which acts as 
lubricant.  
The areola contains smooth muscle which on contraction compresses the base of 
the nipple. At each pregnancy breast enlarges and reaches their greatest during 
lactation. After menopause, the atrophy of glandular tissue and is replaced by 
fibrosis.
 
FIG-6: SAGGITAL SECTION OF FEAMLE BREAST AND ANTERIOR 
THORASIC 
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MICROSCOPIC ANATOMY OF BREAST: 
GLANDULAR TISSUE: 
 The glandular portion of breast is composed of fibrous, adipose and 
epithelial tissue divided into 15-20 lobes which are arranged in a radial pattern. 
Each lobe is drained by a lobe specific lacticiferous duct. Some of these ducts may 
join, so that no more than 5 to 10 openings emerge on the surface of the nipple. 
As the collecting ducts proceeds distally from the nipple, they branch and end in 
Terminal duct lobular unit. 
The TDLU is composed of an extra-lobular terminal duct, an intra-lobular terminal 
duct and ductules. The latter are the most distal structures and have a  sac like 
appearance. The lobule is the smallest structural unit of the gland and is 
surrounded with vascular connective tissue. In mature breast, these lobules 
measure approximately 500mm in diameter 
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FIG-7: MICROSCOPIC ANATOMY OF BREAST 
 
FIG-8: TERMINAL DUCT LOBULAR UNIT 
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SUSPENSORY LIGAMENTS OF BREAST: 
“These ligaments are formed from the connective tissue stroma which 
surrounds the ducts and lobules of the mammary gland – in certain areas 
the connective tissue condenses forming ligaments which support the breast, 
extending from the dermis of the overlying skin to the deep fascia.” 
A fibrous condensation of stromal tissues extends from ducts to dermis and 
these are often well developed in upper part of breast as “suspensory ligaments of 
cooper” which assist in support of breast tissue. 
 
ADIPOSE TISSUE: 
It is highly variable in amount present typically in inter lobular stroma and not 
amongst the lobule.  
 
BLOOD SUPPLY: 
“The blood supply to the breast skin depends on the subdermal plexus, which is 
in communication with deeper underlying vessels supplying 
the breast parenchyma. The blood supply is derived from the following”: 
• The internal mammary perforators (most notably the second to fifth perforators) 
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• The thoracoacromial artery 
• The vessels to serratus anterior 
• The lateral thoracic artery 
• The terminal branches of the third to eighth intercostal perforators 
“The superomedial perforator supply from the internal mammary vessels is 
particularly robust and accounts for some 60% of the total breast blood supply. 
This rich blood supply allows for various reduction techniques, ensuring the 
viability of the skin flaps after surgery”. 
 
 
FIG-9: BLOOD SUPPLY OF BREAST  
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VENOUS DRAINAGE: 
Superficial veins radiate from the breast and are characterized by their 
proximity to the skin. They are accompanied by lymphatics and drain to axillary, 
internal mammary and intercostals vessels. 
 
NERVE SUPPLY: 
“Sensory innervation of the breast is dermatomal in nature. It is mainly 
derived from the anterolateral and anteromedial branches of thoracic intercostal 
nerves T3-T5. Supraclavicular nerves from the lower fibers of the cervical plexus 
also provide innervation to the upper and lateral portions of the breast.” 
 
LYMPHATIC DRAINAGE: 
The breast is drained by two sets of lymphatics  
1. Lymphatics of the overlying skin 
2. Lymphatics of the parenchyma of the breast  
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Lymphatics of overlying skin: 
“These drain the integuments over the breast but not the skin over the areola 
and nipple. These pass in radial direction and end in surrounding nodes. Those 
from outer side go to axillary nodes. The skin of the upper part goes to the 
supraclavicular glands. The vessels from skin over the inner part of the breast go to 
internal mammary nodes which are in relation to the veins of that name. The 
lymphatics of the skin over the breast communicate across the midline and a 
unilateral disease may become bilateral by this route.” 
Lymphatics from parenchyma of breast:  
The subareolar lymph plexus of sappy is a collection of large lymph vessels 
situated under the areola. Through the sub-areolar plexus communicate with 
lymphatics of breast tissues it is not collecting zone for the breast lymph. 
The axillary lymph nodes receive 75% of lymph from breast tissue. 
Lymphatics from lobules pass directly outwards in the substance of the breast, 
receive tributaries on the way and pass through the axillary tail to the axilla. 
  Most go to anterior group, few to posterior group and from there to central 
and apical groups. 
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  Lyphatics from the deep surface of breast pass through pectoral muscle on 
their way to axillary and internal mammary nodes. The internal mammary nodes 
receive lymph from medial and inner portions of the breast  
At the level of the first intercostal space, lymphatics connect the right and 
left internal mammary chain behind the manubrium. 
  Even in apparently early breast cancer, that of the outer half of the breast 
may metastasize to the internal mammary nodes without involvement of axillary 
nodes. Some lymph vessels pass down from breast and communicate with sub 
peritoneal plexus.
FIG-10: LYMPHATIC DRAINAGE OF BREAST  
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REGIONAL LYMPH NODES OF BREAST : 
1. AXILLARY LYMPH NODES :  
• ANTERIOR GROUP: or External mammary group – “ it consists 
of four or five nodes that lie along the  lower border of the pectoralis 
minor muscle in association with the lateral thorasic vessels. These 
lymph nodes receive the major portion of lymph draining breast. 
Lymph drains primarily from these lymph nodes into the central 
lymph nodes. However it may pass directly from the external 
mammary nodes into subclavicular lymph nodes.” 
• LATERAL GROUP: or axillary vein group : “it consists of 4 to 6 
lymph nodes that lie medial or posterior to the axillary vein. These 
receive most of the lymph draining from the upper extremity 
.exception being that which drains into the deltopectoral lymph nodes 
called infraclavicular”. 
• POSTERIOR GROUP: or scapular group : Consists of 6 or 7 
lymph nodes that lie along the posterior wall of axillaat the lateral 
border of the scapula in association with the subscapular vessels. It 
mainly receives from the posterior aspect of the neck, the posterior 
aspect of the trunk till iliac crest and posterior aspect of shoulder 
region.  
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• CENTRAL GROUP: they are embedded in the fat of axilla, usually 
posterior to the pectoralis minor muscle. They receive lymph from 
the three preceeding gropus and may receive afferent lymphatics 
directly from the breast. Lymph from central nodes passes to the 
apical nodes. It is usually located between posterior and anterior 
axillary folds. 
• APICAL GROUP: consists of 6 to 12 lymph nodes located partly 
posterior to the upper border of the pectoralis minor and partly 
superior to it. They extend into the apex of the axilla along the medial 
side of axillary vein. The efferent lymphatics from from 
subclavicular lymph nodes unite to form subclavian trunk. It may 
directly join the internal jugular vein, the subclavian vein, or the 
junction of these two. 
• INTERPECTORAL OR ROTTER’S GROUP: “1 to 4 small 
lymph nodes that are located between the pectoralis major and minor 
muscles in association with the pectoral branches of thoracoacromial 
vessels”.  
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2. LEVELS OF AXILLARY LYMPH NODES : 
• LEVEL –I : These are nodes located lateral to or below the lower border of 
pectoralis minor and include anterior, lateral and posterior group 
• LEVEL-II: These are nodes located deep to or behind pectoralis minor and 
include the central group.  
• LEVEL-III: These are nodes located medial to or above the upper border 
of pectoralis minor and include apical nodes. 
 
FIG-11:  LYMPHATIC DRAINAGE OF BREAST  
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FIG-12: LYMPH NODES IN BREAST WITH VARIOUS LEVELS OF 
AXILARY LYMPH NODE                          
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 Breast Quadrants: 
The surface of breast is divided into 4 quadrants for the purpose of location and 
Description of the breast lumps such as tumors or cysts. 
 
 
FIG-13: QUADRANTS OF BREAST  
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PHYSIOLOGY OF BREAST: 
 From birth until puberty, there is no difference in the breast tissue of both 
maleand female. The breast tissue is made up of connective tissue & mammary 
glands. 
But physiological changes occur in the female breast with puberty, during 
every menstrual cycle and then pregnancy and menopause. During puberty, 
increased hormones such as estrogens stimulate the secondary sexual characters, 
including the development of breast parenchyma. The breasts grow in both size 
and amount of the mammary glands & of fatty and connective tissues deposited in 
the breast. 
In females, with each menstrual cycle hormone fluctuations occur which are 
Important for the  developing breast tissues. After every ovulation, the female body 
Prepares for pregnancy and thus a change in the hormone pattern is noted. One of 
the purposes of this preparation is to stimulate growth of the mammary glands to 
make the breast glands ready for milk production if the female became pregnant.  
The increase in size is responsible in some women to feel breast tenderness 
during part of their menstrual cycle called cyclical mastalgia, During menstruation, 
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the hormone levels drop to low level and the breast glands decrease to their normal 
size. 
“During pregnancy, increased estrogen stimulates breast growth, both 
Increasing the size & number of glands and the fatty tissue amount in the breasts as 
Part of the body's preparedness for lactation and breast feeding. Prolactin & the 
Placental hormones stimulate milk production during pregnancy, but milk 
secretion is prevented by the high levels of oestrogen & progesterone.” 
  But at child birth, the oestrogen and progesterone levels drop to very low 
levels so that milk secretion can start to occur. 
“After menopause, the levels of oestrogen levels in the female body reduce 
and the breast tissue is no longer stimulated. Thus, the breast content changes from 
mostlyof glands & dense connective tissue to fatty tissue mostly.” 
 The dense breast tissue of younger women is responsible for difficulty to 
see through on mammographic study,that is why screening mammograms are not 
ideal in females under 40 yrs of age, as masses may be missed. 
As the fat content in the breast tissue increases with age, it became easier to 
Detect lumps and changes Consistent with malignancy on mammogram. Branchig 
of the lactiferous ducts occur in the breast tissues during menstruation and 
pregnancy. 
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Even though breast is prepared for secretion by mid pregnancy, breasts do 
not produce milk before the baby is born. 
Colostrum is a yellowish or white colored pre milk fluid, which is secreted 
from the nipples during the last trimester of pregnancy and during initial few days 
after child birth. 
  Colostrum is especially rich in proteins, immune antibodies, and a 
Growth factors acting on the infant's intestines for proper development. The elderly 
Female breasts are small because of the decreasing fat content and the atrophic 
changes of glandular tissue. 
1. PROGESTERONE AND ESTROGEN :  
The growth of breast at puberty and during pregnancy is associated with changes in 
the level of estrogen and progesterone 
Actions of estrogen: 
• Epithelial proliferation 
• Darkens the nipple 
• Sensitizes the breast for activity of progesterone 
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 Progesterone by itself has little action, but causes acinar multiplication and 
enlargement of breast already stimulated by estrogen. The ovaries throughout the 
intra menstrual phase of normal cycle produce estrogen, the amount secreted 
increases at ovulation and again shortly before menstruation. During pregnancy the 
main source of estrogen is placenta. 
The corpus luteum of the ovary produces progesterone. It starts increasing from the 
time of ovulation till shortly before the onset of menstrual bleeding. During 
pregnancy placenta produces large quantities of progesterone. Progesterone given 
alone produces no change, but when given together with estrogen, marked 
glandular development occurs. However, no secretory change occurs. 
2. PROLACTIN :  
• Structural growth and secretory differentiation  
• Development of mammary immune system 
• Initiation and maintainance of milk secretion  
• It causes alveolar hyperplasia 
3. PLACENTAL ROLE: placenta produces both estrogen and progesterone. 
Placenta is very important organ of internal secretion in relation to breast 
development during pregnancy. Its hormones stimulate proliferation of both 
ducts and glandular cells.  
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FIG-14: Physiological changes in Breasts 
The breast at different physiologic stages. The central column contains three-
dimensional depictions of microscopic structures. 
A. Adolescence. B. Pregnancy. C. Lactation. D. Senescence 
39	
	
 
 
FIG-14: ANDI CLASSIFICATION BENIGN BREAST DISEASE 
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PATHOLOGICAL CLASSIFICAION OF BENIGN BREAST DISEASE:           
DEVELOPMENTAL DISORDERS: 
1. Supernummary nipples and breast  
2. Accessory axillary breast tissue 
3. Congenital inversion of nipple 
4. Macromastia 
INFLAMMATIONS: 
1. Acute mastitis  
2. Periductal mastitis  
3. Mammary duct ectasia  
4. Fat necrosis 
5. Granulomatous mastitis  
6. Others (tb, syphilis,hydatid disease) 
FIROCYSTIC CHANGES: 
1. Cysts  
2. Fibrosis 
3. Adenosis 
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       PROLIFERATIVE BREAST DISEASE : 
1. Epithelial hyperplasia  
2. Sclerosing adenosis 
3. Small duct papilloma 
        BENIGN TUMORS : 
1. STROMAL TUMORS – Fibroadenoma & phylloides tumor 
2. EPITHELIAL TUMOR – large duct papilloma 
       OTHERS:  
Lipoma, Hamartoma, Mondor’s disease, Gynaecomastia 
Developmental Abnormalities Ectopic breast 
• Mammary heterotopia - It is both supernumerary and aberrant breast tissue 
and is the most common congenital abnormality of the breast. 
Supernumerary breast tissue is seen mostly along the milk line;  
Common sites are the chest wall, vulva, and axilla. 
• Polythelia-  components of nipple  
• Polymastia- involves areola and glandular tissue.  
• However, an anatomic location outside the milk line should not preclude a 
diagnosis of ectopic breast tissue, because there are many well-documented, 
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unusual sites of such tissue, including the knee, lateral thigh, buttock, face, 
ear, and neck. 
•  “Aberrant breast tissue” is usually located near the breast, most 
commonly in the axilla. They usually have a nipple and areola and a 
separate duct system from that of the normal breast. When the nipple is 
absent, the presence of the accessory breast tissue is difficult to identify. The 
accessory breast tissue responds in the same way as normal breast tissue to 
physiological influences. The absence of a duct system may cause 
symptoms of obstruction during lactation and may be mistaken clinically for 
a carcinoma. 
•  Recognition of ectopic breast tissue is important because it can serve as a 
milieu for the development of a variety of benign and malignant lesions 
encountered in the normal breast. Ectopic breast tissue is more prone to 
malignant change and occurs at an earlier age; however malignancy in 
ectopic breasts  is very rare  
• Macromastia- Excessive breast growth can be seen in pregnancy as well as 
during adolescence.  
• Hypoplasia- Underdevelopment of the breast ; it is congenital - usually 
associated with genetic disorders, such as ulnar- Turner’s syndrome,  
congenital adrenal hyperplasia mammary syndrome , Poland’s syndrome,.  
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There are some recent studies suggesting the association of ulnar-mammary 
syndrome and breast cancer. 
•  Acquired hypoplasia, is usually iatrogenic, most commonly subsequent to 
trauma or radiotherapy. 
• Amastia- The complete absence of both breast and nipple.  
• Amazia- presence of only nipple without breast tissue. 
1. DISORDERS OF DEVELOPMENT :  
FIBROADENOMA:  
• Fibroadenoma is a benign encapsulated tumor seen in young females of 
age group 15-25 yrs 
• It is CONidered as polyclonal hyperplasia when compared to phylloides 
which is monoclonal hyperplasia  
• Most common benign tumor occurring below the age of 30 years  
• It is an aberration in the normal development of a lobule 
• It is bilateral in 20% cases and 20% cases may be multiple  
• Juvenile fibroadenoma shows rapid growth with stromal and epithelial 
hyperplasia and it does’nt show any alteration in stromal epithelial 
balance or cellular atypia or periductal cellular concentration  
• Greater than 5cms size is CONidered as giant fibroadenoma 
• Microscopical types – intracanalicular and pericanalicular  
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• It presents as a painless swelling in one of the quadrants, which is usually 
smooth,firm,nontender,well-localized and moves freely within the breast 
tissue(breast mouse) 
• Investigations – mammography-well localized smooth regular shadow; 
FNAC; ultrasound- to confirm the solid nature 
• Excision is the treatment of choice ; those which are small(<3cms) 
single/age<30yrs can be left alone with regular follow up with ultrasound 
at 6 months interval. 
  FIBROADENOSIS:  
• It presents with cyclical mastalgia with nodularity 
• Microscopic changes are stromal fibrosis, microcyst formation, glandular 
proliferation, hyperplasia of ducts and acini, papillomatosis within the ducts 
often apocrine metaplasia  
• It is a benign breast lesion with composite histological features of a 
fibroadenoma and fibrocystic changes that represent a morphological stage 
in the development of fibroadenoma.  
• It may be charecterised by microscopic fibroadenomatoid foci intermingled 
with dilated ducts, epitheliosis and adenosis 
  
45	
	
Adolescent hypertrophy:  
• It is gross stromal hyperplasia at the time of breast development  
• An excessively large breast is Considered as a disorder whereas 
gigantomastia is at the disease end of spectrum 
2. DISORERS OF INVOLUTION :  
CYST FORMATION:  
• It is involution of the lobular epithelium  
• If the stroma involutes too quickly then epithelial acini remains and can lead 
to the development of cyst  
            SCLEROSING ADENITIS:  
• It is Considered as a disorder of either the proliferative or the involutional 
phase of breast cycle as the histological changes are both prolierative and 
involutional  
• There is characteristic distortion of epithelial acini by fibrous tissue  
 DUCT ECTASIA:  
• It is common in the post menopausal women  
• Usually presents as periductal mastitis  
• There will be weakening of the muscular layers of the ducts with eventual 
secondary dilatation. 
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• The presenting symptoms are nipple discharge, nipple retraction, 
inflammatory masses and abscess  
• Periductal fibrosis can occur in the absence of duct ectasia or inflammation 
and represents the normal involutional process 
EPITHELIAL HYPERPLASIA:  
• More common in the postmenopausal women  
• It is a disorder of normal involution  
• Expression of estrogen receptor alpha in surrounding normal lobules doubles 
the cancer risk previously associated with epithelial hyperplasia. 
NIPPLE INVERSION:  
 It is a disorder of development of the terminal ducts  
MAMMARY DUCT FISTULA: 
            Nipple inversion  
 
            Terminal duct obliteration  
 
                         Recurrent subareolar abscess  
 
                  Mammary duct fistula    
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EPITHELIAL HYPERPLASIA OF PREGNANCY:  
• Papillary projections give rise o bilateral bloody discharge  
• There will be marked hyperplasia of the duct epithelium which occurs 
during pregnancy  
BENIGN DUCT PAPILLOMA:  
 It occurs during the years of cyclical activity and is associated with highest 
risk of cancer  
NON-PROLIFERATIVE DISORDERS OF BREAST:  
1. CYST AND APOCRINE METAPLASIA :  
• Fluid filled and epithelized spaces are seen  
• It is usually multifocal  
• Bilateral  
• Never malignant  
• Originates from terminal duct lobular unit or from the obstructed 
ectactic duct  
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2. DUCT ECTASIA : 
• Involves large and intermediate ductules of the breast  
• Palpable dilated ducts with desquamated ductal epithelium and with  
associated proteinaceous secretion   
• The characteristic histological feature is periductal inflammation  
• It mimics invasive ductal carcinoma  
 
3. MILD DUCTAL EPITHELIAL HYPERPLASIA : 
• There will be increased number of stromal cells  
• Epithelial hyperplasia that lacks apocrine or atypical features 
4. CALCIFICATIONS :  
• It is common in ductal, lobular and stromal tissues of the breast  
• Diffuse microcalcifications are common in sclerosing adenosis 
 
5. FIBROADENOMAS AND RELATED LESIONS : 
• They are well marginated pseuoencapsulated tumors composed of 
abundant stroma and epithelial elements and have a wide spectrum of 
proliferative and non proliferative histological changes  
• FIBROADENAMATOSIS- they have features of both fibroadenoma 
and fibrocystic changes  
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• Fibroadenomatoid foci intermingled with dilated ducts , epitheliosis 
and adenosis  
• Tubular adenoma is a well defined freely mobile tumor composed of 
benign epithelial elements with sparse stromal elements  
• Others are hamartroma and lipoma  
 PROLIFERATIVE BREAST DISORDERS WITHOUT ATYPIA:  
1. SCLEROSING ADENOSIS :  
•  There is Proliferation of the glandular elements 
• Increase in the number of the cinar structure and there will be fibrosis 
of the lobular stroma  
• It usually ocuurs in the context of multiple microscopic cysts and 
diffuse microcalcifications  
2. RADIAL SCAR AND COMPLEX SCLEROSING LESIONS :  
• Radial scar usually originates at the terminal duct branching  
• It is usually small in size upto 1cm  
• Complex sclerosing lesions are usually large mass  
• There will be central sclerosis and varying degree of epithelial 
proliferation with apocrine metaplasia and papilloma formation 
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3. FLORID DUCTAL EPITHELIAL HYPERPLASIA :  
• It is the most common proliferative lesion of the breast  
• There will be increase in the cell number within the ducts with a 
proliferation of cells  
4. INTRADUCTAL PAPILLOMA :  
• It is a tumor of the major lactiferous ducts and is most commonly seen 
in premenopausal women. 
• Patients usually present with serous or bloody discharge  
• Microscopic features are it is composed of multiple branching papillae 
with central fibrous vascular core lined by epithelial cells  
• Excision should be done as it has high risk of malignancy which 
accounts to about 24.5% ductal carcinoma in situ  
    ATYPICAL PROLIFERATIVE LESIONS:  
1. ATYPICAL LOBULAR HYPERPLASIA :  
• The cytology of atypical lobular hyperplasia is usually bland with 
rough and lightly stained eosinophilic cytoplasm. 
• Pathognomic feature is uniformity and roundness of the cell 
population  
• There is no significant distortion of the lobular unit  
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• The incidence is greater when compared to that of perimenopausal 
women  
• Those with atypical lobular hyperplasia and a family history of breast 
cancer in a 1st degree relative has a risk of invasive caner twice that of 
the patient who presents with atypical lobular hyperplasia alone 
2. ATYPICAL DUCTAL HYPERPLASIA : 
• It is diagnosed when atypia is present and when cytological evidence 
for ductal carcinoma insitu is absent. 
• It should have a uniform population of cells  
• Smooth geometric spaces between the cells or micropapillary 
formation with uniform cellular placement  
• There should be hyperchromatic nuclei  
• It has an intermediate risk for the development of carcinoma breast 
CLINICAL FEATURES OF BENIGN BREAST DISEASE: 
 Benign breast disease usually presents as lump, mastalgia, nipple 
discharge and breast enlargement 
1. LUMP:  “is the most common presenting complaint. Two main conditions 
responsible for discrete lump in breast are fibroadenoma in young women 
and cysts in peri or post menopausal women”. 
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• Other causes of lump are phylloides, galactocele, fat necrosis, chronic 
abscess and skin & vascular lesions elsewhere in the body. In fibrocystic 
disease, there may be past history of similar complains.  
• Galactocele generally is associated with recent or past history of lactation. In 
fat necrosis history of trauma is always not evident; sometimes it may be 
unrecognized. 
•  Most of the fibroadenomas and cysts are not visible on inspection because 
of their small size. Whereas a giant fibroadenoma, phylloides tumor or 
galactocele may be evident on inspection. On palpation fibroadenoma 
appreciated as discrete lump with firm CONistency and they move freely 
within breast tissue.  
• Cysts are also mobile but not to the extent of fibroadenoma. The striking 
feature of phylloides tumor is its large size with stretchy skin overlying skin. 
Skin may be warm with prominent subcutaneous veins and sometimes 
ulceration due to pressure necrosis. Galactocele presents as lump in the 
central or peri areolar region with cystic CONistency. 
2. MASTALGIA: There are two distinct group of patients with these 
symptoms. One group has symptoms that bear a definite relation to the 
menstrual cycle( cyclical mastalgia) and other no such relation ( non-cyclical 
mastalgia) 
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• CYCLICAL MASTALGIA: this is the most common type of breast pain 
causing discomfort for a varying period of time before menstruation. It 
accounts for 67% of cases. Median presenting age is about 35 years. The 
pain of cyclical mastalgia is frequently but not always bilateral and is 
located in the upper, outer quadrants. It is poorly localized and may radiate 
across the chest wall into the axilla or down the inside of arm. 
• NON-CYCLICAL MASTALGIA: This is even less well defined than 
cyclical counterpart. It occurs in pre and postmenopausal women, with a 
median age of presentation of 45years, as well as having no close relation to 
the menstrual cycle. Non-cyclical mastalgia tends to be more chronic, 
unilateral and located in the medial quadrants of the breast or the peri-
areolar regions. It is not associated with lumpiness to the same degree as 
cyclical mastalgia and the pain frequently described as “burning” or 
“dragging” rather than heavy feeling. Upto 50% of patients with non-
cyclical mastalgia have pain that arises not from the breast but from 
surrounding musculoskeletal structures.  
3. NIPPLE DISCHARGE: Any secretion from the nipple causes anxiety to 
the patients.  A nipple discharge is defined as a true discharge that is 
expelled directly out of the mammary duct or ducts and appears on the 
surface of the nipple. Human milk, breast cyst fluid and nipple aspirate 
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fluid(NAF) all contain variety of steroids, protein harmones, polypeptide 
growth factors, these inclue prolactin,calcitonin, epidermal growth factor 
and transforming growth factor alpha. The concentration seems to fluctuate 
throughout the menstrual cycle and the exact significance is unclear. 
DISCHARGE FROM THE SURFACE:  
• Pagets disease  
• Skin disease ( eczema,psoriasis) 
• Rare causes (chancre) 
      DISCHARGE FROM SINGLE DUCT: 
      BLOOD STAINED: 
• Intraductal carcinoma 
• Intrauctal papilloma 
• Duct ectasia 
SEROUS( ANY COLOR) 
• Fibrocystic disease  
• Duct ectasia  
• Carcinoma 
55	
	
      DISCARGE FROM MORE THAN ONE DUCT: 
BLOOD STAINED: 
• Carcinoma 
• Ductal ectasia 
• Fibrocystic disease  
PURULENT: infections 
SEROUS: 
• Fibrocystic disease  
• Duct ectasia  
• Carcinoma  
MILK: lactation  
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INVESTIAGTIONS: 
NON INTERVENTIONAL: 
1. Mammography  
2. Ultrasound  
3. Doppler flow study  
INTERVENTIONAL: 
1. FNAC 
2. Core needle biopsy 
3. Incisional biopsy 
4. VAB ( vacuum assisted biopsy) 
5. Ductograpgy  
6. Image guided needle biopsy  
In any patient who presents with a breast lump or other symptoms the 
diagnosis should be made by combination of clinical assessment, 
radiological imaging and tissue sample sent for either cytology or 
histopathological analysis called as “Triple assessment” 
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MAMMOGRAPHY: 
 The most commonly used breast imaging procedure is Mammography. It 
uses low dose film/screen technique delivers a dose as low as 0.1 rad per study.  
The two major types of mammography are screening mammography and 
diagnostic mammography. 
 Screening mammography is used to detect unsuspected breast cancer in 
asymptomatic women. 
 Diagnostic mammography is used to evaluate breast of patients with 
symptoms, such as lump or nipple discharge. Mammography is also used to 
guide interventional procedures including prebiopsy needle localization, needle 
aspiration, core biopsy and ductography. 
The screening mammography CONists of two views  
1. Mediolateral oblique view  
2. Craniocaudal  
ABNORMAL MAMMOGRAPHIC FINDINGS: 
 Mammography can give its features as masses and calcifications and also 
gives features which are important clues to their etiology. A mass is defined as 
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space occupying lesion that is seen on atleast two mammographic projections. 
Calcification is the deposition of calcium salts in tissues. 
Technical reporting of Mammography: 
Assessment incomplete (category 0) is reserved for screening examinations in 
which an additional image evaluation, such as utrasonography or special 
mammographic or spot compression views are required. The following categories 
are those used for assessment of diagnostic or screening examinations that does not 
require additional investigations. 
• Category 1 : negative is reserved for a mammographic examination with no 
findings 
• Category 2 : an assessment of benign is used when the interpreter wishes to 
describe an obviously benign finding,such as involuting fibroadenoma with 
coarse “popcorn” calcification or multiple secretory calcifications. 
• Category 3 : A probably benign assessment includes findings that have a 
very high probability of being benign  
• Category 4: A suspicious abnormality is not characteristic of breast cancer 
but has a reasonable probability of being malignant 
• Category 5: The highly suggestive of malignancy group includes lesion that 
have a high probability of being malignant  
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• Category 6 : known  biopsy proven malignancy 
XEROMAMMOGRAPHY: It is identical to mammography except that it is 
recorded on xenographic plates rather than conventional transperancy. The 
image produced is positive rather than negative. 
MAGNIFICATION MAMMOGRAPHY: This technique enhances the 
sharpness of detail and increases diagnostic accuracy for breast cancer. The 
optimal magnification is 1.5 times life size. Margins of breast masses and the 
degree and specificity of microcalcifications are clearly defined. 
DIGITAL MAMMOGRAPHY: This records the image electronically in a 
digital format rather than directly on film. The image is kept in a computer and 
can be either displaced on a fluorescent monitor or transferred to hard copy. It 
has the advantage of image magnification on the display monitor to use 
computer aided diagnosis and teleradiography 
ULTRASOUND: It is particularly helpful in young women with dense breast 
in whom mammography is difficult to interpret and in differentiating cystic and 
solid masses. The importance of ultrasound lies in the resolution of equivocal 
mammography. Ultrasound is an excellent method of guiding some 
interventional procedures. Ultrasound features suggestive of benign breast 
disease include absence of malignant findings like echogenic pseudocapsule, 
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hyperechogenicity, homogenous interval echos and enhanced echos distal to the 
masses. Malignant lesions have an irregular shape,indistinct margin, 
spiculations, microcalcifications, height greater than width, hypo-echogenicity 
and shadowing. 
DOPPLER STUDIES : Information about vascular anatomy is obtained, 
including the number of vessels and their arrangement and configuration as well 
as the anatomical relationships between the vessels and the lesions. Blood flow 
in malignant lesions is enhanced.  
MAGNETIC RESONANCE MAMMOGRAPHY: Conventional 
mammography may not be able to detect lesions in the breast of younger 
women or in a previously operated breast. Moreover susceptibility to radiation 
induced breast cancer in a younger patient is potential risk. For these groups, it 
offers a potentially significant advantage. The contrast enhancement has also 
now become available. 
INTERVENTIONAL PROCEDURES: 
FNAC: It is an outpatient procedure. It involves the use of fine needle(22 or 23 
guage) with a syringe to aspirate cells for a suspicious area, smearing them on a 
glass slide,fix and stain for cytological examination. However specific 
histological diagnosis may be impossible because of the inability to maintain 
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architectural patterns with aspirations. Even if adequate specimen is obtained, a 
definitive diagnosis is always not possible and it cannot differentiate insitu 
carcinoma from invasive breast carcinoma. 
CORE NEEDLE BIOSPY: The core needle biopsy is similar to FNAC but the 
caliber of the needle is bigger, it removes a small cylinder of tissue. There are 
two special devices used for taking core biopsy, they are mammotome and 
advanced breast biopsy instrument 
INCISIONAL BIOPSY: In few cases, when FNAC or core needle biopsy is 
inconclusive, an incisional biopsy may be needed to remove a bit of tissue or 
whole tissue for examination under a microscope. 
VACUUM ASSISTED BIOPSY : It is a recent diagnostic and therapeutic 
procedure. After injecting loacal anaesthesia on the skin and subcutaneous 
tissue a 5mm incision is made over the skin, mammotome is held firmly on the 
lump and mammotome is connected to the vacuum pump. 
IMAGE GUIDED NEEDLE BIOPSY: this acts as an alternative to surgical 
biopsy for mammographically detected abnormalities. Needle biopsy of occult 
lesions can be guided by sterotactic mammography or ultrasonography. 
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DUCTOGRAPHY: it is the injection of contrast medium into the lacticiferous 
ducts in an attempt to preoperatively determine the nature, location and extent 
causing serous or bloody discharge.  
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FIG-15: APPROACH TO A CASE OF BENIGN BREAST DISEASE  
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   MANAGEMENT :              
         NUTRITIONAL THERAPY:  
1. Methyl xanthenes should be avoided- caffeine, theophylline & theobromin 
2. Low dietary fat- as fat increases endogenous harmone levels  
3. Applicaton of evening primrose oil: evening primerose oil ( 9% gamma-
linoleic acid) bypasses the delta-6 desaturation step and hence will have 
symptomatic relief.  
4. Iodine : absence of iodine may render the epithelium of terminal intralobular 
ducts more sensitive to estrogen secretion 
Administration of sodium bound iodine (6mg) is useful  
             ENDOCRINE THERAPY:  
•  ANDROGENS :  
• TESTOSTERONE – 40 mg twice daily  
• DANAZOL – attenuated androgens and 2-3 isoxazol derivative of 
17alpha-ethinyl testosterone 
Inhibits estrogen & progesterone receptors in breast, 
hypothalamus and pituitary; inhibits multiple enzymes of 
ovarian steroidogenesis; inhibits midcycle surge of LH in 
premenopausal women 
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Dose – 100mg twice a day for two months  not more than 
6months  
Side effects – muscle cramps, acne, hot flushes, hirsutism, 
voice change, increased libido, depression 
It is contraindicated in thromboembolic patients. 
• GESTIRONE :  Inhibits midcycle gonadotropin surge and acts 
directly on pituitary gland, ovary and directly on the estrogen receptor 
of mammary gland. 
•  LHRH AGONISTS : Antigonadotropic action and direct inhibiton of 
ovarian steroidogenesis  
Side effects – hot flushes, myasthenia , depression, vaginal atrophy, 
decreased libido, hypertension  
•  THYROID HARMONES :  antagonizes the effects of estrogen at the 
pituitary receptor levels of lactotrophs such as TRH 
Estrogen dominance will cause prolactin responsiveness to TRH in 
patients with mastalgia 
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  NON ENDOCRINE THERAPY :  
• BROMOCRIPTINE : acts as a dopamine agonist on the hypothalamo-
pitutary axis and eventually will cause suppression of  prolactin 
secretion 
side effects – seizures, stroke 
• CABERGOLINE 
• ANALGESICS – NSAIDS etc 
• TAMOXIFEN – 20mg/day for 3 months  
Side effects – hot flushes, vaginal discharge, endometrial 
carcinoma 
 Post treatment patient should be reviewed after 2 to 3 months to assess the 
response to treatment using the patients view and pain chart 
The CARDIFF BREAST PAIN (CBS) – enables the response to be graded 
CBS-1 : An excellent response leaving no residual pain  
CBS-2 : A substantial response  
CBS-3 : A poor response leaving substantial residual pain  
CBS-4: No response 
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 MATERIALS AND METHODS:  
• SOURCE OF DATA : A TOTAL OF 100 PATIENTS DIAGNOSED AS 
BENIGN BREAST DISEASE BOTH IN OUT-PATIENT BASIS AND 
THOSE WHO WERE ADMITTED IN GENERAL SURGERY WARD 
WERE SELECTED FOR THE STUDY AND SERUM PROLACTIN 
LEVELS AND TSH & T4 LEVELS ESTIMATION WAS DONE . 
• ELIGIBILITY CRITERIA :  
• INCLUSION CRITERA : PATIENTS OF REPRODUCTIVE AGE 
GROUP DIAGNOSED AS  
(A) FIBROADENOMA  
(B) FIBROADENOSIS  
(C) FIBROCYSTIC BREAST DISEASE  
               PATIENTS CONENTED FOR INCLUSION IN THE STUDY 
ACCORDING TO THE DESIGNATED PROFORMA  
• EXCLUSION CRITERIA : ALL THE PATIENTS PRESENTING 
WITH LUMP SUGGESTIVE OF MALIGNANCY,ULCERATIVE 
BREAST LESION, PREGNANCY & LACTATION  
PATIENTS NOT CONENTED FOR INCLUSION IN THE STUDY  
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• SELECTION OF STUDY SUBJECTS : ALL PATIENTS DIAGNOSED 
AS HAVING BENIGN BREAST DISEASE COMING UNDER THE 
INCLUSION CRITERIA FOR A  TIME PERIOD (JANUARY 2016 TO 
SEPTEMBER 2016) AND THEIR SERUM PROLACTIN LEVELS AND 
TSH LEVELS  
• METHOD OF STUDY : PROSPECTIVE STUDY  
• CONENT : INDIVIDUAL WRITTEN & INFORMED CONENT  
• ANALYSIS : STATISTICAL ANALYSIS                                    
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CASE PROFORMA:  
1. NAME & AGE : 
2. ADDRESS : 
3. IP/OP NO: 
4. MASTALGIA : CYCLICAL/ NON-CYCLICAL 
5. SITE OF INVOLVEMENT :  
6. MENSTRUAL CYCLE : 
7. AGE OF MENARCHE : 
8. NIPPLE DISCHARGE: SEROUS/SEROSANGUINOUS/BLOODY/MILK 
9. LUMP:  
10. H/O PREVIOUS SURGERY: 
11. FAMILY HISTORY: 
12. H/O ORAL CONTRACEPTIVES: 
13. DRUG ALLERGY: 
14. DIET HISTORY: 
15. OBSTETRIC HISTORY: 
16. FAMILY HISTORY: 
17. GENERAL EXAMINAION:  
 
70	
	
18. LOCAL EXAMINATION OF BREAST: 
 
 
 
19. PROVISIONAL DIAGNOSIS: 
20. INVESTIGATIONS: 
• USG/FNAC : 
• FNAC 
• SERUM PROLACTIN: 
• TSH & T4 : 
21. RESULTS :  
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RESULTS: 
The present study of 100 cases of Benign Breast Disease was studied during a 
period of January 2016 to September 201 . Both outpatient and inpatient basis 
patients diagnosed as Benign Breast Disease(i.e Fibroadenoma,Fibroadenosis & 
Fibrocystic Breast disease) were selected and serum prolactin and TSH & T4 
levels estimation was done. This study mainly focuses on the PREVALENCE OF 
HYPERPOLACTINEMIA AND HYPOTHYROIDISM IN BENIGN BREAST 
DISEASE. 
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Fig-16:Table showing  Age distribution in patients with benign breast disease  
   51 patients out of the 100 patients selected for the study were of the age 
group 21-30yrs which is the commonest age group and age more than 40yrs being 
the least common age group which was seen in 6 patients selected for the study 
 
AGE No Of Cases 
< 20 12 
21-30 51 
31-40 31 
> 40 6 
Total 100 
Mean 28.84 
SD 6.841 
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Fig-17: Bar chart showing the age distribution in benign breast disease 
patients selected for the study 
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Fig-18: table show the associated clinical features of patients with benign 
breast disease; lump being the commonest features among all the patients, 
mastalgia in 44 patients & nipple discharge in 17 patients out of 100 selected 
for study 
CLINICAL FEATURES 
 
LUMP 100 
PAIN 44 
 NIPPLE DISCHARGE 17 
 
 
 
Fig-19: Pie chart showing the clinical features of patients with benign breast 
disease; lump being the commonest followed by mastalgia and nipple discharge 
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Fig-20: Tabular column showing the distribution of the symptoms of patients 
with benign breast disease included in the study in months  
 7to 9 months being the common duration of symptoms most commonly 
associated with fibroadenosis and fibrocystic breast disease  
 
 
DURATION IN MONTHS  NO  OF CASES  
<3 26 
4--6 25 
7--9 28 
10--12 13 
> 12 8 
Total 100 
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Fig-21 : Bar chart showing duration of symptoms in patients with benign 
breast disease in months  
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Fig-22: table showing size of the lump associated with the patients of benign 
breast disease included in the study ;2 to 3 cms being the common 
presentation ; most commonly associated with cases of fibroadenoma 
 
 
SIZE OF THE LUMP 
LEFT No. of Cases RIGHT No. of Cases 
- 43 - 48 
2cms RUQ 20 2cms LUQ 21 
3cms RUQ  33 3cms LUQ 29 
4cms RUQ 4 4cms LUQ 2 
Total 100   100 
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Fig-23 : cylindrical chart showing size of the lump associated with the patients 
of benign breast disease included in the study 
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Fig-24: table showing the consistency of patients with benign breast disease                  
( fibroadenoma, fibroadenosis, fibrocystic breast disease) 
 Consistency was firm in all cases with lump; hence ruling out any malignant 
lesion  
CONISTANCY No. of Cases 
HARD 0 
FIRM 100 
Total 100 
Fig-25: table showing the number of cases of benign breast disease wherein 
ultrasound was used as an imaging modality  
ULTRASOUND No. of Cases 
NIL 17 
Fcs & b/l 14 
Fdn 45 
Fds & b/l 24 
Total 100 
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Fig-26 : cylindrical chart showing the number of cases of benign breast 
disease wherein ultrasound was used as an imaging modality  
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Fig-27 : Table & cylindrical chart showing the number of cases of benign 
breast disease wherein mammography was used as an imaging modality and 
its relationship with age of the patient   
MAMMOGRAPHY No. of Cases 
NIL 82 
Fcs & Fcs b/l 9 
Fds & Fds b/l 9 
Total 100 
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Fig-28: Table and pie chart  showing that FNAC was diagnostic for all cases 
of benign breast disease; out of the 100 patients selected for the study FNAC 
showed there were 45 cases of Fibroadenoma, 33 cases of Fibroadenosis, 22 
cases of Fibrocystic breast disease 
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FNAC No. of Cases 
Fcs 22 
Fdn 45 
Fds 33 
Total 100 
 
 
Fig-29: Table and Pie chart showing the prevalence of Hyperpolactinemia in 
100 cases of benign breast disease studied which was 22 % 
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FNAC DISTRIBUTION 
Fcs Fdn 
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Normal reference range of serum prolactin for the study was 4.79-23.3 ng/l 
Higher than normal reference range was seen in 22 cases out of the 100 selected 
for study  
PROLACTIN 
No. of 
Cases fds fds B/L fcs fcs B/L fdn Nil 
< 23 78 16 5 10 1 31 15 
>23 22 2 1 3 0 14 2 
Total 100             
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Fig-30 : Table shows the number of patients having a TSH  value lower than 
the reference range ; normal reference range of TSH is 0.51-4.30 uIU/ml 
25 patients out of the 100 selected for the study had TSH value more than 4.30 
uIU/ml 
TSH 
No. of 
Cases fds fds B/L fcs fcs B/L fdn Nil 
< 4.2 75 14 3 10 0 33 15 
> 4.2 25 4 3 3 1 12 2 
Total 100             
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Fig-31 : Table show the number of cases out of the 100 cases selected for the 
study had a T4 value which was either equal to or more than 4.6 ug/dl 
 Normal reference range of T4 is 4.6-12 ug/dl 
  20 patients out of the 100 studied had a T4 value of less than 4.6ug/dl and  
5 patients had a value which was equal to 4.6ug/dl; this has significance when 
compared with TSH values to rule out overt hypothyroidism and subclinical 
hypothyroidism                             
75 
25 
TSH 
< 4.2 
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T4 
No. of 
Cases fds fds B/L fcs fcs B/L fdn Nil 
T4 < 4.5 25 6 3 4 1 13 2 
> 4.5 80 14 3 11 0 33 16 
4.5 5  1 1   - 1   2 -  
Total 100             
 
• When compared with TSH values 20 patients were CONidered as having 
overt hypothyroidism without any presenting symptoms ; this group of 
patients had a TSH value of more than 4.30 uIU/ml and T4 value of less 
than 4.6. 
• Patients having TSH value of more than 4.30 uIU/ml and T4 value equal to 
4.6 with symptoms of hypothyroidism  were CONidered as having 
subclinical hypothyroidism   
Out of the 100 patients included in the study 5 patients were CONidered as 
having subclinical hypothyroidism  
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Fig-32 : Bar chart show the number of cases out of the 100 cases selected for 
the study had a T4 value which was either equal to or more than 4.5 ug/dl 
 Normal reference range of T4 is 4.5-12 ug/dl 
  20 patients out of the 100 studied had a T4 value of less than 4.5ug/dl and  
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Fig-33 : Table and Pie chart  showing the management of the patients included in 
the study; excision was done in 45 patients which were diagnosed as 
Fibroadenoma and the rest i.e. 55 patients were treated  conservatively with 
medical management and they included Fibroadenosis and Fibrocystic breast 
disease  
REMARKS No. of Cases 
excision 45 
Conservative 55 
Total 100 
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                                                 DISCUSSION:  
Benign breast disease results from an imbalance or inappropriate target gland 
response to changing tide of hormonal stimulation. In our study 100 patients 
diagnosed as having benign breast disease were included from a period of January 
2016 to September 2016. 
 Patients were diagnosed as having benign breast disease after Triple Assessment 
of the patient (thorough clinical examination, ultrasound/mammography & 
FNAC). 
51 patients out of the 100 patients selected for the study were of the age group 21-
30yrs which is the commonest age group and age more than 40yrs being the least 
common age group  which was seen in 6 patients selected for the study. 
clinical features of patients with benign breast disease; lump being the commonest 
feature  among all the patients, mastalgia in 44 patients & nipple discharge in 17 
patients out of 100 selected for study. 
Serum prolactin level estimation was done for all the patients included in the study 
and results revealed that 22% of the patients had Hyperprolactinemia, out of which 
14 cases were fibroadenoma, 2 cases were unlilateral fibroadenosis, 1 case was 
bilateral fibroadenosis and 3 cases were unilateral fibrocystic breast disease. 
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TSH & T4 level estimation was done and 25 % patients had overt 
hypothyroidism without any symptoms suggestive of Hypothyroidism irrespective 
of the clinical feature of benign breast disease out of which 13 cases were 
Fibroadenoma, 6 cases were Fibroadenosis and 6 cases were Fibrocystic breast 
disease in the above study and 5 % patients had subclinical Hypothyroidism with 
symptoms suggestive of hypothyroidism. 
All the patients were evaluated by a thorough history and clinical 
examination of breasts and thyroid. Patients were asked to grade their mastalgia in 
three categories like absent,mild and severe (which disturbs daily activity). Patients 
were also asked about the subtle symptoms of hypothyroidism like weight gain, 
listlessness, menorrhagia, mood changes, muscle cramps, feeling unwell and 
fatigability. 
Both hypothyroidism and hyperprolactinemia was seen in 15 cases out of 
which 4 cases were fibrocystic breast disease, 4 cases were fibroadenosis and 7 
cases were fibroadenomas. 
Hence looking at the prevalence of hyperprolactinemia and hypothyroidism 
in the patients selected for the study there could be an association between thyroid 
dysfunction and benign breast disease and also association of raised serum 
prolactin levels with benign breast disease  
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Prevalence of hyperprolactinemia in our study was 22 %  
Prevalence of hypothyroidism in our study was 25%  
Both normal and pathological breast tissue exhibit high concentrations of sodium 
iodide sypmorter(NIS), peroxidase and deiodinase indicating active involvement of 
breast tissue in iodine metabolism. There are no guideline regarding monitoring of 
Thyroid function during workup of Benign breast disease cases. Our study is to 
look for the prevalence of hypothyroidism in benign breast disease. 
From our study we concluded that  
• It could be end organ hypersensitivity to normal circulating levels of 
prolactin or other hormones or environmental factors that is responsible for 
benign breast disease and pharmacological manipulation of prolactin in 
patients having raised serum levels can provide relief from symptoms  
•  Both normal and pathological breast tissue exhibit high concentrations of 
sodium iodide sypmorter(NIS), peroxidase and deiodinase indicating active 
involvement of breast tissue in iodine metabolism. Our study strengthens the 
association of thyroid dysfunction with benign breast disease. Hence benign 
breast disease patients should be screened for hypothyroidism and simple 
correction of hypothyroidism may result in significant clinical improvement 
of benign breast disease patients. 
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KEY TO MASTER CHART: 
• C/F- clinical features  
• Symp- symptoms suggestive of hypothyroidism 
• CON- consistency 
• USG- ultrasound 
• MAM- Mammogram  
• FNAC- Fine needle aspiration cytology 
• PROL- serum prolactin  
• TSH- Thyroid stimulating hormone 
• T4- Thyroxine 
• Fdn- Fibroadenoma 
• Fds- Fibroadenosis 
• Fcs- Fibrocystic breast disease  
• LUQ- Left upper quadrant  
• RUQ- Right upper quadrant  
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         C/ F         
                     
SIZE OF 
THE 
LUMP                   
S 
NO NAME 
AGE/
SEX IP/OP 
LUM
P 
PAI
N DIS 
DURATIO
N  
SYM
P LEFT RIGHT CON USG MAM 
FNA
C 
PRO
L TSH T4 Rx 
1 
pandiyam
mal 30/F 126541 + - - 3 months  - 
3cms 
RUQ  - firm  Fdn  - Fdn 12.4 3.4 5.2 EX 
2 lakshmi 24/F 126896 + - - 1 year  - - 
2cms 
LUQ firm Fdn - Fdn 25.2 6.4 3 EX 
3 Latha  26/F 65421 + + + 4 months  - 
3cms 
RUQ  
2cms 
LUQ firm Fds b/l - Fds 13.2 2.4 5.4 CON 
4 
panchavar
nam 30/F 54654 + - - 4 months  - - 
3cms 
LUQ firm Fds - Fds 14.2 3.4 6.4 CON 
5 meena  20/F 126548 + - - 3months  - 
2cms 
RUQ - firm Fdn - Fdn 13.8 2.6 7.2 EX 
6 
pandiyam
mal 32/F 65421 + + - 2 years  - 
4cms 
RUQ - firm Fcs - Fcs 13.6 3.22 6.4 CON 
7 lakshmi 28/F 56423 + - - 1 year  + - 
2cms 
LUQ firm Fdn - Fdn 26.2 6.2 4.5 EX 
8 gayathri 20/F 123546 + - - 3 months  - 
3cms 
RUQ  - firm Fdn - Fdn 12 2.4 6.2 EX 
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9 
meenamm
al 30/F 128654 + - - 5 months  - 
3cms 
RUQ  - firm Fcs - Fcs 25.2 6.5 3.2 CON 
10 Latha  34/F 56457 + + - 4 months  - - 
3cms 
LUQ firm Fds - Fds 13.4 3.12 5.4 CON 
11 
mariyamm
al 32/F 65445 + - - 6 months  - - 
4cms 
LUQ firm Fcs - Fcs 14.2 4.2 6.4 CON 
12 lakshmi 30/F 65498 + + - 8 months  - 
2cms 
RUQ - firm Fdn - Fdn 13.4 3.4 5.4 EX 
13 meena 22/F 128965 + - - 4 months  - - 
3cms 
LUQ firm Fdn - Fdn 25.4 2.44 7.2 EX 
14 priya 20/F 124758 + - - 3 months  - 
2cms 
RUQ - firm Fdn - Fdn 14.2 2.6 5.4 EX 
15 
ponnamm
al 38/F 124578 + + + 2 years  - 
3cms 
RUQ  
4cms 
LUQ firm - 
Fds 
b/l Fds 13.6 3.5 6.4 CON 
16 lakshmi 28/F 126584 + + - 1 year  - - 
3cms 
LUQ firm Fcs - Fcs 12.4 3.6 5.4 CON 
17 
pandiyam
mal 34/F 126557 + - - 6 months  - - 
3cms 
LUQ firm Fdn - Fdn 14 6.5 4.1 EX 
18 
mariyamm
al 30/F 54658 + - + 9 months  - 
3cms 
RUQ  - firm Fcs - Fcs 26.4 6.6 2.9 CON 
19 
Ponnamm
al 20/F 134525 + - - 4 months  - - 
3cms 
LUQ firm Fdn - Fdn 15.4 3.8 7.8 EX 
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20 sasikala 34/F 142651 + - - 6 months  - 
2cms 
RUQ - firm Fdn - Fdn 16.69 3.6 7.6 EX 
21 
mahalaksh
mi 31/F 145624 + + - 7 months  - 
3cms 
RUQ  - firm Fcs - Fcs 17.73 1.49 7.8 CON 
22 pandiselvi 19/F 145456 + - - 3 months  - - 
2cms 
LUQ firm Fdn  - Fdn 41 3.51 8.2 EX 
23 
kumaresh
wari 40/F 145234 + + - 2 years  - 
3cms 
RUQ  
3cms 
LUQ firm - 
Fds 
b/l Fds 22.8 2.38 7.4 CON 
24 maria 36/F 65425 + + + 1 year  - 
3cms 
RUQ  - firm - Fcs Fcs 18.4 3.2 7.6 CON 
25 jabakani 41/F 146242 + + + 6 months  - - 
3cms 
LUQ firm - Fds Fds 19.5 2.8 7.8 CON 
26 vidhya 37/F 146420 + + - 7 months  - - 
3cms 
LUQ firm - Fds Fds 20.5 2.6 7.5 CON 
27 
vishnu 
priya 34/F 146832 + + - 8 months  - 
2cms 
RUQ - firm Fds - Fds 21.2 3.1 8.2 CON 
28 saroja 43/F 146521 + + - 1 year  - - 
3cms 
LUQ firm - Fcs Fcs 16.5 2.4 8.5 CON 
29 rajeshwari 48/F 147201 + + - 2 years  - - 
2cms 
LUQ firm - Fds Fds 18.4 2.6 8.8 CON 
30 manju 38/F 147461 + + - 1 year  - 
2cms 
RUQ - firm - Fcs Fcs 19.4 2.8 7.6 CON 
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31 kavitha 37/F 65821 + - - 9 months  - 
3cms 
RUQ  
3cms 
LUQ firm - 
Fcs 
b/l Fcs 25.2 5.4 3.4 CON 
32 sulochana 21/F 69856 + - - 2 months  - - 
2cms 
LUQ firm Fdn - Fdn 25.4 3.4 7.4 EX 
33 Ramya 27/F 145234 + - - 3 months  - 
3cms 
RUQ  - firm Fdn - Fdn 22.4 5.4 3.2 EX 
34 Indra 20/F 153452 + - - 3 months  - 
3cms 
RUQ  - firm Fdn - Fdn 21.2 3.6 7.8 EX 
35 kirthika 18/F 154262 + - - 2 months  - - 
3cms 
LUQ firm Fdn - Fdn 16.4 3.4 8.2 EX 
36 Pushpam 25/F 153422 + - - 6 months  - 
2cms 
RUQ - firm Fdn - Fdn 18.4 3.8 8.4 EX 
37 Meenakshi 20/F 72132 + - - 3 months  - - 
3cms 
LUQ firm Fdn - Fdn 22.2 5.2 3.1 EX 
38 Ambujam 42/F 154642 + + - 2 years  - 
3cms 
RUQ  - firm - Fds Fds 17.8 3.4 7.6 CON 
39 
Thavaman
i 22/F 156451 + - - 3 months  - 
2cms 
RUQ - firm Fdn - Fdn 19.4 3.8 8.2 EX 
40 Kalaivani 25/F 154875 + - - 8 months  - 
3cms 
RUQ  
3cms 
LUQ firm Fds b/l - Fds 25.4 5.4 2.9 CON 
41 Anguthai 30/F 154569 + + + 1 year  - - 
2cms 
LUQ firm Fds - Fds 20.6 3.4 7.6 CON 
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42 Aasha 21/F 154697 + - - 3 months  + 
3cms 
RUQ  - firm Fdn - Fdn 22.1 5.4 4.5 EX 
43 Kamala 44/F 154678 + + + 7 months  - 
3cms 
RUQ  - firm - Fcs Fcs 21.4 3.5 7.6 CON 
44 Kavitha 21/F 154687 + - - 3 months  - - 
2cms 
LUQ firm Fdn - Fdn 25.4 4.2 7.8 EX 
45 Sundari 18/F 159875 + - - 6 months  - 
3cms 
RUQ  - firm Fdn - Fdn 18.6 3.6 8.4 EX 
46 Ganga 29/F 159652 + + - 1 year  - - 
3cms 
LUQ firm Fds - Fds 25.4 6.5 3.2 CON 
47 
Lakshmid
evi 37/F 156478 + - - 2 years  - 
2cms 
RUQ - firm - Fds Fds 18.6 3.9 9.2 CON 
48 
Muthumar
i 32/F 154687 + - - 8 months  - 
3cms 
RUQ  - firm Fcs - Fcs 19.2 3.2 8.4 CON 
49 Sridevi 24/F 157894 + + - 3 months  - - 
2cms 
LUQ firm Fdn - Fdn 17.5 5.4 3.2 EX 
50 Rajammal 35/F 154987 + - - 6 months  + 
3cms 
RUQ  
2cms 
LUQ firm Fds b/l - Fds 25.2 5.6 4.5 CON 
51 Meena 23/F 154687 + + - 3 months  - 
2cms 
RUQ - firm Fdn - Fdn 19.4 3.2 7.8 EX 
52 Gayatri 31/F 165413 + - - 8 months  - - 
3cms 
LUQ firm Fcs - Fcs 20.2 5.6 3.4 CON 
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53 Vani 23/F 165464 + + - 6 months  - 
2cms 
RUQ - firm Fdn - Fdn 18.4 3.2 7.6 EX 
54 
Rajeshwar
i 32/F 167895 + - + 9 months  - - 
3cms 
LUQ firm Fds - Fds 19.6 3.5 8.2 CON 
55 Amala 32/F 164579 + + - 9 months  - 
3cms 
RUQ  - firm Fds - Fds 25.4 5.4 3.2 CON 
56 Gunarani 38/F 169874 + + + 9 months  - 
3cms 
RUQ  - firm - Fcs Fcs 20.6 3.2 7.8 CON 
57 Malavika 25/F 162451 + - - 4 months  - - 
2cms 
LUQ firm Fdn - Fdn 25.6 5.6 2.8 EX 
58 Nagaveni 35/F 165412 + + - 1 year  - - 
3cms 
LUQ firm - Fds Fds 19.6 3.2 7.4 CON 
59 
Rajeshwar
i 45/F 165478 + - - 2 years  + 
3cms 
RUQ  
2cms 
LUQ firm Fcs b/l Fcs Fcs 18.4 5.6 4.5 CON 
60 
Subbamm
al 40/F 165478 + + - 6 months  - - 
2cms 
LUQ firm - Fds Fds 19.4 3.4 7.5 CON 
61 Panchu 30/F 162314 + - - 3 months  - - 
3cms 
LUQ firm Fdn - Fdn 25.8 5.8 3.6 EX 
62 Vimala 23/F 165478 + - - 5 months  - 
2cms 
RUQ - firm Fdn - Fdn 21.2 3.2 7.8 EX 
63 Radha 25/F 167845 + - - 4 months  - 
2cms 
RUQ - firm Fdn - Fdn 21.2 3.4 8.2 EX 
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64 Pavithra 23/F 165478 + - - 3 months  - 
3cms 
RUQ  - firm Fdn - Fdn 25.4 4.2 7.6 EX 
65 Suganya 26/F 165478 + + - 8 months  + 
4cms 
RUQ - firm Fds - Fds 19.4 5.4 4.5 CON 
66 
Petchiman
i 32/F 165478 + + - 7 months  - - 
3cms 
LUQ firm Fds - Fds 18.6 3.5 8.4 CON 
67 Kaviya 26/F 165478 + - - 3 months  - - 
2cms 
LUQ firm Fdn - Fdn 26.2 3.6 7.8 EX 
68 Prema 28/F 165488 + - - 8 months  - 
3cms 
RUQ  - firm Fcs - Fcs 21.2 3.2 8.4 CON 
69 Vinutha 25/F 165478 + - - 1 year  - - 
2cms 
LUQ firm Fdn - Fdn 20.2 5.6 3.2 EX 
70 Hemalatha 35/F 172456 + + + 7 months  - 
3cms 
RUQ  - firm Fcs - Fcs 25.4 5.6 3.2 CON 
71 Nithya 32/F 174562 + + - 9 months  - - 
2cms 
LUQ firm Fcs - Fcs 19.6 3.7 7.5 CON 
72 Rani 26/F 174562 + + - 1year  - 
3cms 
RUQ  
2cms 
LUQ firm Fds b/l - Fds 18.4 5.4 3.4 CON 
73 Nirmala 30/F 178954 + + + 9 months  - 
3cms 
RUQ  - firm Fds - Fds 20.4 2.8 8.6 CON 
74 Latha 27/F 174562 + - - 3 months  - - 
2cms 
LUQ firm Fdn - Fdn 25.4 3.2 9.2 EX 
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75 Thamarai 35/F 174521 + + - 9 months  - 
3cms 
RUQ  - firm Fds - Fds 16.2 5.2 3.2 CON 
76 Sumathi 21/F 178541 + + + 9 months  - 
4cms 
RUQ - firm Fds - Fds 16.8 3.4 8.2 CON 
77 
Mahalaksh
mi 30/F 178542 + - - 3 months  - - 
2cms 
LUQ firm Fdn - Fdn 15.4 3.6 7.8 EX 
78 Nasrin 21/F 174561 + - - 4 months  - - 
3cms 
LUQ firm Fdn - Fdn 25.4 5.4 3.2 EX 
79 Vanthana 18/F 174521 + - - 5 months  - 
3cms 
RUQ  - firm Fdn - Fdn 18.6 3.4 8.2 EX 
80 Indra 20/F 174521 + - - 3 months  - - 
2cms 
LUQ firm Fdn - Fdn 19.6 3.6 8.6 EX 
81 Vanitha 26/F 178542 + + + 8 months  - 
3cms 
RUQ  - firm Fds - Fds 20.1 5.6 3.4 CON 
82 Kavitha 30/F 174521 + + - 9 months  - 
3cms 
RUQ  
2cms 
LUQ firm Fds b/l - Fds 21.4 3.6 7.8 CON 
83 Sujatha 21/F 179856 + - - 3 months  - 
2cms 
RUQ - firm Fdn - Fdn 25.6 3.4 8.2 EX 
84 Suguna 25/F 179985 + + - 8 months  - - 
3cms 
LUQ firm Fds - Fds 19.4 3.6 7.5 CON 
85 Manjula 25/F 179994 + - - 6 months  - 
2cms 
RUQ - firm Fdn - Fdn 18.6 3.4 8.2 EX 
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86 Meenakshi 35/F 182452 + - + 9 months  - - 
3cms 
LUQ firm - 
Fcs 
b/l Fcs 25.4 5.6 3.4 CON 
87 sasikumari 23/F 184552 + - - 3 months  - 
3cms 
RUQ  - firm Fdn - Fdn 18.4 3.4 7.8 EX 
88 Radha 27/F 186645 + + - 9 months  - 
2cms 
RUQ - firm Fds - Fds 19.2 3.6 8.2 CON 
89 Meenakshi 24/F 186547 + - - 5 months  - - 
3cms 
LUQ firm Fcs - Fcs 17.5 3.2 8.4 CON 
90 Jeyasree 30/F 184562 + + + 6 months  - 
3cms 
RUQ  - firm Fds - Fds 18.6 3.4 8.6 CON 
91 Ramya 27/F 184552 + - - 3 months  - 
2cms 
RUQ - firm Fdn - Fdn 26.4 2.8 8.4 EX 
92 Leelavathi 31/F 189564 + + - 8 months  - - 
3cms 
LUQ firm Fds b/l - Fds 19.2 2.7 7.8 CON 
93 Brintha 35/F 189545 + + + 1 year  - 
2cms 
RUQ - firm - Fcs Fcs 20.1 2.8 7.4 CON 
94 Banupriya 18/F 195462 + - - 3 months  - - 
3cms 
LUQ firm Fdn - Fdn 19.2 5.4 3.4 EX 
95 Rekha 23/F 194521 + - - 4 months  - 
2cms 
RUQ - firm Fdn - Fdn 17.8 2.8 7.8 EX 
96 Veeramani 33/F 196542 + + - 9 months  - - 
3cms 
LUQ firm Fds - Fds 18.2 2.4 8.4 CON 
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97 sudha 34/F 196542 + + + 1 year  - 
4cms 
RUQ - firm Fds - Fds 19.4 5.4 3.2 CON 
98 veena 29/F 197852 + + - 2 years  - - 
3cms 
LUQ firm Fcs - Fcs 20.2 3.6 8.6 CON 
99 Aasha 25/F 198562 + - - 3 months  - 
2cms 
RUQ - firm Fdn - Fdn 21.4 3.4 9.2 EX 
100 Selvi 29/F 198546 + - - 6 months  - - 
3cms 
LUQ firm Fdn - Fdn 18.6 5.4 3.2 EX 
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